Already a Bloomberg.com user?
Sign in with the same account.
Don't have an account?
Help! I can't access my account.
Amylin Pharmaceuticals, the maker of the diabetes drug Bydureon, rejected a $3.5 billion unsolicited takeover bid from Bristol-Myers Squibb earlier this year
On Air Now
In The Loop with Betty Liu
©2014 Bloomberg L.P. All Rights Reserved. Made in NYC